WO2005023276A1 - Pharmarzeutischer wirkstoff gegen brustkrebs - Google Patents
Pharmarzeutischer wirkstoff gegen brustkrebs Download PDFInfo
- Publication number
- WO2005023276A1 WO2005023276A1 PCT/DE2004/001988 DE2004001988W WO2005023276A1 WO 2005023276 A1 WO2005023276 A1 WO 2005023276A1 DE 2004001988 W DE2004001988 W DE 2004001988W WO 2005023276 A1 WO2005023276 A1 WO 2005023276A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- active
- enzyme
- synergistic
- antagonistic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- biogenic poisons Needs coordinated, so-called biogenic, poisons. These biogenic poisons have found their place in the interplay of different types of life in the course of long development periods.
- Plants or animals can have a primarily toxic effect through the production of toxins or can only acquire secondary toxicity by ingesting toxic substances from the living or inanimate environment.
- Tumors the most dangerous and feared diseases of our time, are currently being combated in a very radical and less environmentally friendly way.
- the following can be used as simple, characteristic keywords: steel, radiation and chemotherapy.
- a pharmaceutical active ingredient is known from DE 199 61 141 A1, in which it has been found that components of the spider venom from spiders of the Sicaridae family can be used for the treatment of tumor diseases. Mainly, a peptide toxin from the poison of this type of spider, a further antagonistic substance obtained from the poison and / or a combination of these components are used medically.
- This active ingredient can be used for the treatment of tumor diseases and in parallel or in support of tumor operations and residual tumor tissue can be destroyed.
- genetically modified body cells tumor cells
- the active ingredient in question recognizes the changed surface structure of such cells and kills them without complications. cannot be used pharmaceutically.
- Breast cancer or breast cancer is a malignant one
- proliferative mastopathy The initially benign proliferation of the glandular lobes of the mammary gland and the connective tissue, the so-called proliferative mastopathy, represents a further risk factor.
- proliferative mastopathy a further risk factor.
- breast cancer development are also a high-fat food, the influence of ionizing radiation, tobacco and alcohol consumption, and the long-term use of female sex hormones.
- a computed tomography, a nuclear medical examination of the bones in question (bone scintigraphy) and an ultrasound examination of the liver provide indications of possibly existing daughter tumors.
- the result of microscopic tissue examinations (histology) provides information about the exact tumor type and the degree of the respective aggressiveness of the tumor (grading).
- the examination of the surgically obtained tumor and the lymph nodes allows an overview of the extent of the tumor seeding, i.e. the course of metastases.
- breast cancer is rare in men, but it is usually only discovered at an advanced stage. Since the fascia of the pectoral muscle is often already reached or exceeded by the tumor, the pectoral muscle must also be removed in such cases. As with women, the extent of axillary lymph node involvement plays a crucial prognostic role. Therapy and follow-up care is no different from that of a woman. However, the prognosis is more unfavorable than that of women because of the mostly advanced stage of discovery.
- the active substance according to the invention is essentially produced from a combination of a mixture of a homeopathic substance and a substance obtained from the purified oral secretions of one of the following animal species from the Varanidae family (monitor lizards): a) Varanus storii or dwarf monitor lizard b) Varanus gilleni or Gillen - monitor lizard c) Varanus acanthurus or barbed monitor lizard d) Varanus kingorum or king monitor lizard e) Varanus boehmei (also boehmi)
- Monitor lizards form their own family in the subordination of lizards (Sauria)
- the monitor lizards form a family close to the snakes. You have some
- Body types that are very similar to snakes One is, for example, the long, deeply split tongue. With the tip of the tongue, the monitor lizards can absorb the finest fragrances from the air. This leads them into the so-called Jacobsonian
- Olfactory organ Thanks to their very well-developed sense of smell, the monitor lizards can easily follow the traces of their prey.
- the monitor lizard's body is long and relatively wide and flat.
- the legs are strong and the feet have strong curved toes.
- the tail is long and very strong among the larger representatives.
- the head sits on a clearly recognizable shark and is flat, the snout is rounded.
- the skin looks a bit too big for the body because it is on the neck and
- the lizards' scales are colored very differently.
- the color palette ranges from gray to muted green to brown. Some species have a pronounced pattern, such as horizontal stripes and dots.
- monitor lizards are very versatile. All monitor lizards are good swimmers and divers. They put their legs back against the body and steer with their long tail. Apart from adult Komodo dragons, all species, some of which are almost pure
- Tree dwellers are good climbers. Despite their sometimes massive shape
- Monitor lizards are good and fast runners.
- the monitor lizards are mostly carnivores, but they also have a preference for
- the mouth secretion is obtained from the types of monitor lizards mentioned under a) to e).
- this is not a biogenic poison, but another biogenic agent. It is important to ensure that no secretions from the throat are used.
- This oral secretion is freeze-dried in amounts of 2 to 10 mg, processed under sterile conditions and dissolved in 50 ml of the homeopathic substance Tarantula D4. This mixing takes place in a homeopathic manner by shaking both substances ten times towards the center of the earth.
- the D dilution levels are made by filling 1/10 of the stock solution with 9/10 alcohol and then shaking. This gives the first dilution D1. Again take 1/10 of this dilution and shake it with 9 parts of alcohol, and you get a D2. This procedure is continued until high potencies such as D 200 finally arise. Nevertheless, they are highly effective medicines. However, in order to search for an explanatory model, one has to say goodbye to physics, which works with simple linear substance-related theses. A combination with an active ingredient described in an earlier patent application can also be used for the use of the active ingredient according to the invention when breast cancer begins to develop.
- the active ingredient according to the invention can be an antagonistic or synergistic and / or penetrating substance to the respective oral secretion from the. Oral secretions, of the species concerned.
- the antagonistic or synergistic substance is preferably a phospholipase or a hyaluronidase or a combination of both substances.
- the antagonistic or synergistic substance is a mixture of the phospholipases and hyaluronidases and / or toxins present in other species.
- the oral secretion and the substance which is antagonistic and / or synergistically active for this purpose are preferably obtained by a fractionation process from the total cocktail of the oral secretion, and it is further preferred that the pharmaceutical active substance contains an oral secretion and a substance which has an antagonistic or synergistic effect which consists of different fractions.
- the effect of the pharmaceutical active ingredient can advantageously be tailored to the type of polyp or ulcer to be treated.
- the oral secretion and the substance having an antagonistic and / or synergistic effect can be obtained by known fractionation processes for the separation of proteins from the mouth saliva. It is preferred that the substances obtained and the substance having an antagonistic or synergistic effect on them are obtained by gel chromatography, HPC, affinity chromatography and / or ion exchange chromatography.
- the oral secretion is present as an active pharmaceutical ingredient in such an amount that the active ingredient has a destructive effect on sick cells.
- the required proportions are chosen so that the active ingredient according to the invention has no or only a slight toxic effect in the patient to be treated.
- the amounts of the active pharmaceutical ingredients must also be matched to the type of illness to be treated and the physical, possibly also psychological, circumstances of the respective patient. The preliminary tests required for such a coordination are to be carried out by the person skilled in the art in the context of animal tests and / or ethically justifiable tests on the patient on the basis of his specialist knowledge and ability.
- an active pharmaceutical ingredient in which the amount of. Oral secretions, and the substance antagonistic or synergistic acting for this purpose, a further amount of homeopathic substance, enzymes and antagonistic or synergistic substance is added, which is selected depending on the disease to be treated.
- the pharmaceutical active ingredient according to the invention contains conventional carriers and auxiliary substances, such as antibiotics, antifungals, antituberculotics, agents against parasites, cytostatics, amino acids, enzymes which promote wound healing and / or mitotic inhibitors.
- antibiotics such as antibiotics, antifungals, antituberculotics, agents against parasites, cytostatics, amino acids, enzymes which promote wound healing and / or mitotic inhibitors.
- the oral secretion and the antagonistic or synergistic substance are used in combination with the homeopathic substance in the pharmaceutical active ingredient according to the invention.
- the present invention also includes derivatives and salts of the substances provided according to the invention.
- the purified oral secretion comprises one or more additions, substitutions and / or deletions of amino acids, it of course having to be ensured that the medicinal effect according to the invention is retained.
- the active ingredient described is obtained by methods customary in chemical process engineering. These include in particular fractionation processes; however, other methods can also be used, for example immunological methods to obtain the desired substances from the. Oral secretions to get out
- the oral secretion is homogenized before the fractionation, and it is further preferred that the fractions are freeze-dried or frozen and preferably lyophilized before further processing.
- a comparison can be made with respect to absolute and relative amounts of the components of the active ingredient according to the invention in vitro on living human cells (healthy and sick) of the tissue type to be treated. Attention to the tendency to spread is of the greatest importance. This can be determined in preliminary tests in comparison to the tissue strength to the tissue surrounding the focus of the disease.
- the mode of action of the oral secretion or individual substances separated therefrom by column chromatography and / or characterized by the molecular weight can be carried out by testing them in corresponding healthy and diseased human cell lines.
- the substances used preferably originate from the same organism as the substances which have an antagonistic or synergistic effect and / or further active substances optionally present.
- the pharmaceutical active substances according to the invention can be produced in such a way that first a raw oral secretion mixture is obtained by methods known per se and fractionation of the raw mixture is carried out by fractionation methods likewise known per se for the separation of proteins. This serves the purpose of the enzymes and the to obtain antagonistic or synergistic substances for this purpose in as separate a form as possible or in separate fractions.
- Various fractions can then be combined to produce a pharmaceutical active ingredient, or individual fractions can be combined with substances originating from other organisms or substances having an antagonistic or synergistic effect. Individual fractions can also be used to produce an active pharmaceutical ingredient.
- Hyaluronidases from snake venoms for example from cobra venoms, can preferably be used as antagonistic substances. This can be combined with one or more fractions from substances obtained from monitor lizards of the types mentioned under a) to e).
- the entire freeze-dried mouth extract taken from a sterile cotton swab is used for each animal.
- Every monitor lizard can be removed every 4 to 6 weeks without stress.
- the tumor process was observed using tumor markers and LSA tests, as well as using imaging techniques.
- Vitamin C-free selenium supplements are suitable as accompanying therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04786711A EP1699472A1 (de) | 2003-09-08 | 2004-09-07 | Pharmarzeutischer wirkstoff gegen brustkrebs |
DE112004002232T DE112004002232D2 (de) | 2003-09-08 | 2004-09-07 | Pharmazeutischer Wirkstoff gegen Brustkrebs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10341307.3 | 2003-09-08 | ||
DE10341307A DE10341307A1 (de) | 2003-09-08 | 2003-09-08 | Pharmarzeutischer Wirkstoff gegen Brustkrebs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005023276A1 true WO2005023276A1 (de) | 2005-03-17 |
Family
ID=34223451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2004/001988 WO2005023276A1 (de) | 2003-09-08 | 2004-09-07 | Pharmarzeutischer wirkstoff gegen brustkrebs |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1699472A1 (de) |
DE (2) | DE10341307A1 (de) |
WO (1) | WO2005023276A1 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1296826A (zh) * | 2000-10-23 | 2001-05-30 | 蔡一青 | 乳腺平忧散 |
CN1435232A (zh) * | 2002-11-04 | 2003-08-13 | 周宝义 | 克塞饮液 |
-
2003
- 2003-09-08 DE DE10341307A patent/DE10341307A1/de not_active Withdrawn
-
2004
- 2004-09-07 WO PCT/DE2004/001988 patent/WO2005023276A1/de not_active Application Discontinuation
- 2004-09-07 EP EP04786711A patent/EP1699472A1/de not_active Withdrawn
- 2004-09-07 DE DE112004002232T patent/DE112004002232D2/de not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1296826A (zh) * | 2000-10-23 | 2001-05-30 | 蔡一青 | 乳腺平忧散 |
CN1435232A (zh) * | 2002-11-04 | 2003-08-13 | 周宝义 | 克塞饮液 |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 200155, Derwent World Patents Index; Class B04, AN 2001-497468, XP002310485 * |
DATABASE WPI Section Ch Week 200408, Derwent World Patents Index; Class B04, AN 2004-072351, XP002310484 * |
Also Published As
Publication number | Publication date |
---|---|
DE112004002232D2 (de) | 2006-07-27 |
EP1699472A1 (de) | 2006-09-13 |
DE10341307A1 (de) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1244462B1 (de) | Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen | |
DE102005038768A1 (de) | Pharmazeutischer Wirkstoff gegen Borreliose | |
WO2006029605A1 (de) | Verfahren und wirkstoff zur bekämpfung von plasmodien | |
WO2005023276A1 (de) | Pharmarzeutischer wirkstoff gegen brustkrebs | |
EP2155335B1 (de) | Pharmazeutische zusammensetzung, verwendung der pharmazeutischen zusammensetzung zur behandlung eines hirntumors, herstellungsverfahren derselben sowie ein kit of parts, enthaltend die pharmazeutische zusammensetzung | |
WO2005009449A1 (de) | Pharmazeutischer wirkstoff gegen warzen, herpes simplex und herpes zoster | |
WO2007060252A2 (de) | Pharmazeutischer wirkstoff zur behandlung von hepatitis, borreliose und multipler sklerose | |
DE10357970A1 (de) | Lösungsmittel für biogene pharmazeutische Wirkstoffe | |
WO2005007177A1 (de) | Pharmazeutischer wirkstoff gegen magengeschwüre | |
DE10330712A1 (de) | Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten | |
EP4233886A1 (de) | Pharmazeutische zusammensetzung zur behandlung eines hirntumors | |
WO2006032245A1 (de) | Pharmazeutischer wirkstoff gegen das hiv - syndro | |
WO2007071716A1 (de) | Pharmazeutische zusammensetzung zur behandlung von tumoren und bestimmten virenerkrankungen | |
EP1754486A2 (de) | Pharmazeutischer Wirkstoff zur Behandlung von Hepatitis, Borreliose und Multipler Sklerose | |
EP1699471A1 (de) | Pharmarzeutischer wirkstoff gegen hepatitis | |
WO2006081808A1 (de) | Pharmazeutischer wirkstoff zur behandlung von multipler sklerose und aids | |
DE10324062A1 (de) | Pharmazeutischer Wirkstoff | |
DE10324861A1 (de) | Pharmazeutischer Wirkstoff | |
WO2005027942A1 (de) | Pharmazeutischer wirkstoff aus schlangengift gegen melanome | |
WO2006034691A1 (de) | Pharmazeutischer wirkstoff zur stärkung des immunsystems | |
DE10322656A1 (de) | Pharmazeutischer Wirkstoff | |
WO2005002494A2 (de) | Pharmazeutischer wirkstoff gegen prostatakarzinome | |
DE102005027478A1 (de) | Pharmazeutischer Wirkstoff gegen Nierenzellkarzinome und dessen Lösungsmittel | |
EP1758602A1 (de) | Pharmazeutischer wirkstoff aus lycosa tarantula | |
DE102004008417A1 (de) | Pharmazeutischer Wirkstoff gegen Lebertumore und Nierenzellkarzinome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1120040022320 Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004786711 Country of ref document: EP |
|
REF | Corresponds to |
Ref document number: 112004002232 Country of ref document: DE Date of ref document: 20060727 Kind code of ref document: P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 112004002232 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004786711 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004786711 Country of ref document: EP |